sees q3 adjusted earnings per share $0.90 to $00.98 excluding items.
q2 adjusted earnings per share $0.91.
q3 adjusted earnings per share $2.01.
sees 2021 capital expenditures in range of $300 million to $330 million.
qtrly adjusted ebitda increased 8% to $148 million.
qtrly total segment core sales growth of 2%.
qtrly core sales to personal care market decreased 1%.
qtrly net sales increased 75% versus q3 2020.
qtrly net sales increased about 60% in food & beverage segment.
qtrly core sales to the prescription market decreased 7%.
compname reports third quarter and fourth quarter 2021 results and announces $30 million share repurchase authorization.
qtrly core sales increased 23%.
qtrly core sales to beauty market increased 28%.
sees q3 revenue up 28% to 30% versus q2.
qtrly core sales of active material science solutions increased 20%.
compname announces agreement to acquire 80% of weihai hengyu medical products, a leading manufacturer of elastomer components for injection devices in china.
